Aytu Biopharma (AYTU) Capital Expenditures (2015 - 2025)

Aytu Biopharma (AYTU) has 9 years of Capital Expenditures data on file, last reported at $17000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures rose 183.33% year-over-year to $17000.0 in Q4 2025; TTM through Mar 2026 was $34000.0, a 93.7% decrease from a year earlier, with the FY2025 full-year figure at $228000.0, down 30.7% from the prior year.
• Capital Expenditures for Q4 2025 stood at $17000.0, roughly flat from $17000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for AYTU reached as high as $329000.0 in Q2 2024 and fell as low as -$13.1 million in Q2 2021.
• Historically, Capital Expenditures has averaged -$1.8 million across 3 years, with a median of $17000.0 in 2025.
• Across the five-year window, Capital Expenditures plunged 123.21% in 2021 and jumped 183.33% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at -$13.1 million in 2021, then surged by 100.05% to $6000.0 in 2024, then soared by 183.33% to $17000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $17000.0 in Q4 2025, $17000.0 in Q2 2025, and $69000.0 in Q1 2025.